Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neutrophil to lymphocyte ratio

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    61 result(s) found for: Neutrophil to lymphocyte ratio. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2021-006055-33 Sponsor Protocol Number: HypoGI Start Date*: 2023-03-05
    Sponsor Name:Medical University of Vienna
    Full Title: Assessing the feasibility of pharmacologically induced hypothyroidism in patients with advanced pancreatic cancer - a pilot study
    Medical condition: Patients with newly diagnosed metastatic pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000082-41 Sponsor Protocol Number: 2021-0486 Start Date*: 2022-03-31
    Sponsor Name:Fundación para la Investigación en Urología
    Full Title: Impact of pitavastatin use in prostate cancer patients treated with new generation androgen therapy: multicenter clinical trial
    Medical condition: We propose a multicenter, prospective, randomized, single-blind clinical trial, without conflict of interest, to determine the clinical benefit of statins (Pitavastatin 2 mg) in prostate cancer pa...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002193-27 Sponsor Protocol Number: COVID-AT Start Date*: 2020-06-15
    Sponsor Name:Cristina Avendano-Sola
    Full Title: Double-blind, randomized, controlled, clinical trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19
    Medical condition: COVID-related Acute Respiratory Distress Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002419-14 Sponsor Protocol Number: IRST189.04 Start Date*: 2015-09-02
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Phase II study of oral PRednisone 5 mg bid plus EVerolimus in patients with metastatic renal cell cancer after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (PRE...
    Medical condition: metastatic renal cell cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000417-16 Sponsor Protocol Number: Uni-Köln-4480 Start Date*: 2021-10-20
    Sponsor Name:University of Cologne
    Full Title: A Phase I / randomized Phase II trial to analyse safety and efficacy of human SARS-CoV 2 specific T lymphocyte transfer in patients with COVID-19 in need of treatment or at risk of severe COVID-19
    Medical condition: Patients who are tested positive for SARS-CoV-2 by PCR from upper or lower respiratory sites and are at increased risk for developing critical disease presenting with moderate disease -WHO ordinal ...
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002184-22 Sponsor Protocol Number: NS3 Start Date*: 2021-05-14
    Sponsor Name:Athens Medical Society
    Full Title: A phase II randomized, single-blind dose study to evaluate the safety and efficacy of exosomes overexpressing CD24 in 10^9 dose versus 10^10 dose, for the prevention of clinical deterioration in pa...
    Medical condition: COVID-19 disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002886-21 Sponsor Protocol Number: UC-0110/1809 Start Date*: 2018-12-11
    Sponsor Name:UNICANCER
    Full Title: A Phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in Metastatic Pancreatic Ductal Adenocarcinoma.
    Medical condition: Metastatic Pancreatic Ductal Adenocarcinoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-004259-17 Sponsor Protocol Number: NS3.1 Start Date*: 2022-03-02
    Sponsor Name:OBCTCD-24 Ltd
    Full Title: A Phase IIb Randomized, Quadruple-blinded Multicenter, Multinational, Placebo-controlled Study to Evaluate the safety and efficacy of exosomes overexpressing CD24 to prevent clinical deterioration ...
    Medical condition: COVID-19 disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001382-10 Sponsor Protocol Number: CS/2015/4775 Start Date*: 2019-01-21
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: Treatment of Barth Syndrome by CARDIOlipin MANipulation (CARDIOMAN): A randomised placebo controlled pilot trial conducted by the nationally commissioned Barth Syndrome Service
    Medical condition: Barth Syndrome is a rare, life threatening, genetic disease which affects young males. It is caused by abnormal fats (lipids) in the powerhouses of cells (mitochondria) and those who suffer with it...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-001121-14 Sponsor Protocol Number: CL010_168 Start Date*: Information not available in EudraCT
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculi...
    Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10072579 Granulomatosis with polyangiitis PT
    20.0 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    20.1 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed) DE (Completed) GB (Completed) AT (Completed) CZ (Completed) NL (Completed) ES (Completed) HU (Completed) DK (Completed) BE (Completed) NO (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-004112-28 Sponsor Protocol Number: URO-EMDA-2022-1 Start Date*: 2023-03-27
    Sponsor Name:Guillem Abad Carratalà
    Full Title: Randomized prospective study of the impact of preoperative instillation of mitomycin-C by electromotive drug administration (EMDA) in patients with non-muscle-infiltrating urothelial carcinoma
    Medical condition: Non muscle invasive bladder tumor
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005009 Bladder cancer stage I, without cancer in situ PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001321-31 Sponsor Protocol Number: 24032020 Start Date*: 2020-04-11
    Sponsor Name:Hospital Universitario de Fuenlabrada
    Full Title: Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients wit...
    Medical condition: Pneumonia due to SARS Cov2 (COVID-19)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002229-27 Sponsor Protocol Number: TACTIC-E Start Date*: 2020-06-09
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Experimental drugs and mechanisms
    Medical condition: SARS-Cov-2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-005020-11 Sponsor Protocol Number: 5000 Start Date*: 2021-05-04
    Sponsor Name:Políclinica Nuestra Señora del Rosario
    Full Title: Randomized multicenter single-blind controlled trial on ozonated blood in COVID-19 severe pneumonia
    Medical condition: Covid-19 pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003009-31 Sponsor Protocol Number: HH007 Start Date*: 2022-12-23
    Sponsor Name:Zealand University Hospital, dept. of Haematology
    Full Title: Atorvastatin for patients with Philadelphia-negative chronic myeloproliferative neoplasms - Essential thrombocythemia, polycythemia vera and prefibrotic myelofibrosis
    Medical condition: Essential thrombocythemia, Polycythemia vera, prefibrotic myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077465 Myeloproliferative neoplasm PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003819-56 Sponsor Protocol Number: 26193789 Start Date*: 2020-06-12
    Sponsor Name:Centre for Surgical Science
    Full Title: Effects of intravenous administered iron in non-anemic iron deficient patients with colorectal cancer. A double blinded clinical randomized trial.
    Medical condition: Iron-deficiency in colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038038 Rectal cancer PT
    20.0 10027433 - Metabolism and nutrition disorders 10022970 Iron deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001972-13 Sponsor Protocol Number: COVID-19HD Start Date*: 2020-05-21
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA
    Full Title: Randomised controlled trial comparing efficacy and safety of high versus low low-molecular weight heparin dosages in hospitalised patients with severe COVID-19 pneumonia and coagulopathy not requir...
    Medical condition: Hospitalized patients with severe COViD-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001577-70 Sponsor Protocol Number: RESCAT Start Date*: 2020-12-28
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA
    Full Title: Allogeneic Mesenchymal Stromal Cell (MSC) Therapy for SARS-CoV-2 Pneumonia: A Prospective Randomized Multicentre Phase I/IIa Open Label Study
    Medical condition: SARS-CoV-2 pneumonia
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004862 10061229 Lung infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000014-42 Sponsor Protocol Number: AQ-PRO-013 Start Date*: 2021-04-24
    Sponsor Name:Aquilon Pharmaceuticals
    Full Title: A randomized, double-blind, placebo-controlled, parallel, trial to determine the safety and efficacy of inhaled AQ001S in the management of acute COVID-19 symptoms
    Medical condition: COVID-19 related respiratory disease
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001684-89 Sponsor Protocol Number: RG_20-030 Start Date*: 2020-05-05
    Sponsor Name:University of Birmingham
    Full Title: CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection.
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004855 10047468 Viral lower respiratory tract infections HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 10:32:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA